The Onco'Zine Dossier


Advertising/Media Partners

View my Flipboard Magazine.


Report a Problem

See any site problems? Let us know if something looks wrong or isn't working. Click here Report a problem


The information contained in Onco'Zine - The International Cancer Network is generally technical in nature and intended for Healthcare Professionals.


Contribute to Onco'Zine - The International Oncology Network by submitting an idea or draft articles to the editor

Join Our Editorial Board!

Are you interested in becoming an Editorial Board member for Onco'Zine - The International Oncology Network and helping to maintain the editorial standards and ethos of this growing journal? To volunteer as an Associate Editor or Contributing Authors, please simply contact us Please enclosing a summary of your research interests and relevant expertise within Oncology and Hematology. We look forward to hearing from you.


Media Partner

Media Partner/Advertisement

Blog Posts

Liquid Biopsies as a Non-Invasive, Assessable Cancer Diagnostic Tool

Posted by Editorial Team on August 9, 2016 at 2:00pm 0 Comments

By Sonio Portillo, Associate Editor, ADC Review/Journal of Antibody-drug Conjugates

When it comes to cancer, late stage diagnosis is correlated with less effective treatment and a poor prognosis. And while cancer research has mainly focused finding cures, there is an unmet need for diagnostic tools that allow…


Distinguished Cancer Researcher Alfred G. Knudson, Jr. Dies at 93

Posted by Editorial Team on July 12, 2016 at 10:00am 0 Comments

Alfred G. Knudson, Jr., MD, PhD (photo), a pioneering cancer researcher who is internationally recognized for his groundbreaking “two-hit” hypothesis, which helped provide the basis for our current understanding of the genetic origins of cancer passed away on July 10, 2016 at 93 years of age.

“The [...] cancer research world as a whole has lost a true visionary with the passing of Knudson. He proposed the two-hit hypothesis many years before the molecular technologies needed…


European Commission Extends Conditional Market Authorization for Brentuximab Vedotin

Posted by Editorial Team on July 11, 2016 at 11:30am 0 Comments

Following a positive opinion from the Committee for Medicinal Products for Human Use issued on May 26, 2016, the European Commission (EC) has extended the current conditional marketing authorization of brentuximab vedotin (Adcetris®/Seattle Genetics/Takeda Oncology). The drug is now…


Men's Health: Focus on Prostate Screening

Posted by Editorial Team on July 6, 2016 at 9:30pm 0 Comments

Contributing Editor: Jon Elion, MD, FACC, Founder/President of ChartWise Medical Systems.

As a cardiologist, it is tempting for me to use this platform to talk about heart disease. Instead I have decided to push myself beyond that, connecting to my cardiology…


Clinical trial of Novel Immune-based Therapy may Benefit Patients with Advanced Pancreatic Tumors

Posted by Editorial Team on July 4, 2016 at 11:00am 0 Comments

While immune therapy has proven effective in treating certain types of cancer, especially lung cancer and melanoma, tumors of the pancreas remain among the most difficult to treat and, so far, are impervious to immune-based therapies.

Now, for the first time, a new study in mice has shown that immunotherapy against pancreatic cancer can be effective when given in conjunction with drugs that break up the fibrous tissue in these tumors.

The study, from Washington University…


Phase III Trial Finds that Anti-interleukin-1 alpha antibody MABp1 Improves Outcomes Significantly over Placebo

Posted by Editorial Team on July 2, 2016 at 11:00am 0 Comments

A novel anti-interleukin 1-alpha antibody has shown a significant impact on symptoms, and a high level of safety and tolerability in patients with advanced colorectal cancer, according to phase III data presented at the European Society for Medical Oncology’s 18th World Congress of Gastrointestinal Cancer in Barcelona, Spain. [1]

Xilonix™ (XBiotech) is the first…


Understanding the impact of Growing Population of Aging Cancer Survivors Critical to Develop Quality Care for this Population

Posted by Editorial Team on July 1, 2016 at 5:00pm 0 Comments

Improved cancer detection and treatment efforts, combined with demographic trends, are creating larger numbers of older cancer survivors who are likely to have other health conditions that impact care and well-being. This is the conclusion of new research published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American…


First Patient Recruited in New Trial with ONCOS-102 in Malignant Pleural Mesothelioma

Posted by Editorial Team on June 30, 2016 at 4:30pm 0 Comments

This week Targovax, a clinical stage immuno-oncology company developing targeted immunotherapy treatments for cancer patients, announced that the first patient has been dosed in a phase Ib/II clinical trial evaluating ONCOS-102 for the treatment of malignant pleural mesothelioma (MPM), a rare type of cancer in the lining of the lung, in combination with pemetrexed and cisplatin.

ONCOS - 102 is a virus-based immunotherapy platform based on engineered…


First Patient Dosed with Combination Trial of the BTK Inhibitor BGB-3111 with the PD-1 Antibody BGB-A317

Posted by Editorial Team on June 29, 2016 at 8:30pm 0 Comments

Dosing of the first patient in a Phase I clinical trial of BGB-3111, a Bruton’s tyrosine kinase (BTK) inhibitor, in combination with BGB-A317, a PD-1 antibody, for the treatment of various B-cell malignancies was initiated earlier this week. This combination study of two internal drug candidates being developed by BeiGene, a clinical-stage biopharmaceutical company focused on developing molecularly targeted and immuno-oncology drugs for the treatment of cancer,  follows an ongoing study of…


Persistent HPV Infection Raises Risk of Anal and Genital Cancers: Risk Can Persist More Than 20 Years After Infection

Posted by Editorial Team on June 29, 2016 at 6:00pm 0 Comments

Women with a history of severe cervical intraepithelial neoplasia, a precancerous condition of the cervix that arises from infection with the human papillomavirus (HPV), had a long-term increased risk of developing anal, vulvar, and vaginal cancer. This is the conclusion of a study,  funded by the Unit of Virus, Lifestyle, and Genes at the Danish Cancer Society Research Center, published in Cancer Epidemiology,…



  • Add Photos
  • View All

Register for free to view all the Onco'Zine - The International Oncology Network content:


Onco'Zine is present here

Bookmark / Share



Meet us on Facebook

© 2017   Created by Peter Hofland, PhD.   Powered by

Badges  |  Report an Issue  |  Terms of Service

Find us on Google+